OakChart

Dr. Reddy's Laboratories Ltd ADR

RDYHealthcare·Drug Manufacturers - Specialty & Generic·India·Large·NYSE·Nov 11 • 3:59 PM ET

14.84-0.02 (-0.13%)
2026-11-12 06:34 CET
Market cap
12,362.80 USD m
Revenue, TTM
3,560.07 USD m
Net income, TTM
303.45 USD m
Free cash flow, TTM
130.43 USD m
EPS diluted, TTM
0.36
P/E
40.78
Compare

Price

RDY against its 20, 50 and 200-day averages
2050200missearnings
12.0013.0014.0015.003.7M7.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26RDYclose 14.8420-day 13.9650-day 12.94200-day 13.2714.8452w high52w low

5.3% under the 52-week high of 15.67 on 26 Jun 2026. 52-week low 11.36 on 22 Jul 2026. Last 15 sessions, 15.5% high to low

Volume 0.75× normal · the line is the 50-bar volume average

Profile

RDY
52-week range, 81% of the way up
11.3615.67

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, and Others. The Global Generics segment refers to the manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment focuses on manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Employees27527
IPOApr 11, 2001
Beta0.31
ATR, 14d0.30
Rel volume0.75
Insider own0.00%
Inst own13.71%

Snapshot

6 groups

Valuation

Index-
Market Cap12.36B
Enterprise Value12.35B
Income303.45M
Sales3.56B
Book/sh4.84
Cash/sh0.96
Dividend Est.0.08 (0.55%)
Dividend TTM0.08 (0.56%)
Dividend Ex-DateJul 24, 2026
Dividend Gr. 3/5Y-9.14% 0.00%
Payout11.04%
Employees27527
IPOApr 11, 2001

Ratios

P/E40.78
Forward P/E24.17
PEG1.92
P/S3.47
P/B3.07
P/C15.54
P/FCF94.78
EV/EBITDA22.47
EV/Sales3.47
Quick Ratio1.40
Current Ratio1.93
Debt/Eq0.19
LT Debt/Eq0.03
Option/ShortYes / Yes

Earnings

EPS (ttm)0.36
EPS next Y0.61
EPS next Q0.13
EPS this Y-15.17%
EPS next Y34.63%
EPS next 5Y12.57%
EPS past 3/5Y-4.82% 15.78%
Sales past 3/5Y7.50% 8.27%
EPS Y/Y TTM-55.45%
Sales Y/Y TTM-10.52%
EPS Q/Q-41.16%
Sales Q/Q-10.05%
EarningsOct 23 AMC
EPS/Sales Surpr.20.45% 1.78%

Ownership

Insider Own0.00%
Insider Trans-
Inst Own13.71%
Inst Trans-5.06%
ROA5.02%
ROE7.52%
ROIC7.31%
Gross Margin45.82%
Oper. Margin8.95%
Profit Margin8.52%
SMA206.28%
SMA5014.72%
SMA20011.87%
Trades-

Technical

Shs Outstand833.07M
Shs Float-
Short Float-
Short Ratio8.69
Short Interest25.30M
52W High15.67 -5.30%
52W Low11.36 30.63%
Volatility2.16% 1.82%
ATR (14)0.30
RSI (14)72.77
Beta0.31
Rel Volume0.75
Avg Volume2.91M
Volume2,176,881

Performance

Perf Week0.47%
Perf Month16.21%
Perf Quarter19.48%
Perf Half Y14.24%
Perf YTD5.70%
Perf Year7.46%
Perf 3Y13.37%
Perf 5Y14.22%
Perf 10Y52.93%
Recom2.26
Target Price14.25
Prev Close14.86
Price14.84
Change %-0.13%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 26, 2026UpgradeJJP MorganUnderweight → Neutral
Oct 26, 2026UpgradeJJefferiesUnderperform → Hold$13.90-6.3%
Sep 29, 2026UpgradeCCitigroupSell → Buy
Apr 23, 2026DowngradeGGoldmanNeutral → Sell
Jun 05, 2025UpgradeHHSBC SecuritiesHold → Buy$16.90+13.9%
Dec 19, 2024DowngradeNNomuraBuy → Neutral
Jan 11, 2024DowngradeJJefferiesBuy → Underperform
Aug 29, 2023DowngradeHHSBC SecuritiesBuy → Hold
May 18, 2023DowngradeBBernsteinOutperform → Mkt Perform
Mar 17, 2023UpgradeBBofA SecuritiesNeutral → Buy

Peers

Mkt cap
TickerCompanyMkt cap
VTRSViatris Inc24.14B
TEVATeva- Pharmaceutical Industries Ltd50.45B
AMRXAmneal Pharmaceuticals Inc7.56B
ANIPANI Pharmaceuticals Inc1.63B
AMPHAmphastar Pharmaceuticals Inc1.22B
ALVOAlvotech1.92B
PRGOPerrigo Company plc2.30B
OGNOrganon & Co3.65B
TAKTakeda Pharmaceutical Co ADR66.58B
HCMHUTCHMED (China) Limited ADR2.63B

Insider trading

1 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
EREZ ISRAELICEOOct 29 '26Proposed Sale14.20460,7266,542,310Nov 02 12:25 PM

Held by

AUM
TickerCompanyAUM
EMOPAB Emerging Markets Opportunities ETFAUM: 1.92B
VWOVanguard FTSE Emerging Markets ETFAUM: 119.40B
AVEMAvantis Emerging Markets Equity ETFAUM: 26.77B
SPEMState Street SPDR Portfolio Emerging Markets ETFAUM: 16.35B
VXUSVanguard Total International Stock ETFAUM: 161.32B
DFEMDimensional Emerging Markets Core Equity 2 ETFAUM: 8.86B
DFAEDimensional Emerging Core Equity Market ETFAUM: 9.14B
DFAXDimensional World ex U.S. Core Equity 2 ETFAUM: 12.02B
VEUVanguard FTSE All-World ex-US ETFAUM: 66.74B
EMEQNomura Focused Emerging Markets Equity ETFAUM: 576.31M

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-10-230.1170.0970.114910.89894.9417
2026Q12026-07-210.0550.0920.056835.68850.5613
2025Q42026-05-110.0280.1190.029785.89886.5714
2025Q32026-01-200.1580.1540.163951.64927.6813
2025Q22025-10-240.1960.1930.1971,002979.7611
2025Q12025-07-230.1970.2140.199988.911,01510
2024Q42025-05-090.2240.2120.221996.16978.210
2024Q32025-01-230.1970.2090.201969.62950.5412
2024Q22024-11-050.1780.2060.180951.11918.0112
2024Q12024-07-270.1990.1920.200916.27875.749
2023Q42024-05-070.1880.1760.189848.07847.6412
2023Q32024-01-290.1990.1770.199868.04833.419
2023Q22023-10-270.2130.1750.215826.44816.237
2023Q12023-07-260.2060.1540.205822.36777.849
2022Q42023-05-100.1400.1150.140767.05745.178
2022Q32023-01-250.1840.1360.182829.77729.1410

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2017FY0.1730.2040.1832,0872,232
2018FY0.3220.3050.3242,1912,179
2019FY0.3100.3410.3312,3032,288
2020FY0.3150.4140.2792,5912,597
2021FY0.3650.4530.3802,7582,805
2022FY0.6600.5750.6742,9952,947
2023FY0.8000.7700.8073,3433,328
2024FY0.7940.7890.8023,8123,755
2025FY0.5380.6470.5513,5133,712
2026FY-0.456--3,692
2027FY-0.614--4,145
2028FY-0.767--4,564

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-30330952.72937.49980.51
2026Q3S2026-10-26430915.77804.89980.51
2026Q3S2026-10-25410905.44804.89980.51
2026Q3S2026-10-24410905.44804.89980.51
2026Q3S2026-10-23410905.44804.89980.51
2026Q3S2026-10-08400895.26804.89939.77
2026Q3S2026-10-05400895.78804.89941.84
2026Q3S2026-10-02412895.78804.89941.84
2026Q3S2026-07-22412895.11804.89941.84
2026Q3S2026-07-06301934.96911.82962.32
2026Q3S2026-07-03301932.64904.86962.32
2026Q3S2026-05-12201917.8904.86930.73
2026Q3S2026-04-22101977.27977.27977.27
2026Q3S2026-01-211001,0611,0611,061

Estimate history

EPS, annual0.1830.3240.3310.2790.380.6740.8070.8020.5820.3639
Period201720182019202020212022202320242025TTM
EPS, quarterly0.180.2010.2210.1990.1970.1630.0290.0560.116
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual2202.9622200.2462462.4152555.5062877.5673060.1633372.2123850.3573801.9563560.07
Period201720182019202020212022202320242025TTM
Sales, quarterly956.883989.845981.924998.4481008.612979.53821.024852.301907.216
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual829.555829.24828.881828.63829.787832.639834.091834.455832.691833.073
Period201720182019202020212022202320242025MRQ
Shares, quarterly833.046834.424834.455834.582834.582832.568832.691832.984833.073
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue3,560.073,801.963,850.363,372.213,060.162,877.572,555.512,462.422,200.25
Cost of Goods Sold Incl. D&A1,929.011,931.591,715.671,493.721,407.141,432.781,257.801,220.241,084.64
Gross Profit1,631.061,870.372,134.691,878.491,653.031,444.791,297.701,242.181,115.60
Selling, General and Administrative Excl. Other1,316.121,344.751,316.471,111.031,006.64984.72868.21840.66843.18
Research and Development228.94256.23307.92262.14228.55220.28208.35201.96205.55
Other Operating Expense-3.57-4.10-3.82-4.08-3.48-2.76-1.91-2.36-7.65
Operating Income318.51529.72822.04771.54649.87462.83431.41403.87280.07
Interest Expense48.4542.3133.4620.6717.7712.8613.0713.8612.71
Unusual Expense7.8814.0620.020.048.70101.50115.68187.71-2.73
Net Income Before Taxes381.70618.88905.62866.39746.71424.07349.31246.40314.70
Income Taxes82.64139.78231.10195.52190.42117.17123.58-20.6852.17
Consolidated Net Income299.10480.61677.08672.64560.90316.33232.19274.98268.79
Net Income From Continuing Operations303.45484.96668.79672.64560.90316.33232.19274.98268.79
Net Income303.45484.96668.79672.64560.90316.33232.19274.98268.79
EPS (Recurring)0.370.590.820.810.680.470.380.490.32
EPS (Basic, Before Extraordinaries)0.360.580.800.810.680.380.280.330.32
EPS (Diluted)0.360.580.800.810.670.380.280.330.32
EBITDA549.82762.921,023.80950.82807.14621.53603.77579.77454.40
Non-Operating Income (Expense)119.52145.52137.06115.55123.3175.5946.6544.1044.61
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.222.583.913.830.005.565.515.14335.98
Price To Earnings Ratio40.7740.7717.1419.3216.8429.1439.5424.2226.44
Price To Sales Ratio2.953.042.863.633.103.224.002.723.06
Gross Margin45.8249.1955.4455.7054.0250.2150.7850.4550.70
Operating Margin8.9513.9321.3522.8821.2416.0816.8816.4012.73
Net Margin8.5212.7617.3719.9518.3310.999.0911.1712.22
Shares Outstanding833.07832.69834.46834.09832.64829.79828.63828.88829.24
Market Capitalization12,362.8012,362.8010,988.7612,213.769,480.439,248.8010,173.926,685.756,717.28

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue907.22852.30821.02979.531,008.61998.45981.92989.85
Cost of Goods Sold Incl. D&A464.35488.41489.09487.15457.17463.10436.32418.92
Gross Profit442.86363.89331.93492.38551.44535.35545.60570.93
Selling, General and Administrative Excl. Other318.42332.69326.84338.17373.86339.80361.47364.44
Research and Development51.1857.1055.5365.1271.0468.9583.7978.85
Other Operating Expense-0.87-0.83-1.14-0.73--1.24--
Operating Income125.3132.036.23154.94177.57196.79184.13206.48
Interest Expense13.0613.2511.5510.6010.399.707.579.69
Unusual Expense1.290.163.393.047.580.008.87-0.05
Net Income Before Taxes129.2658.2721.25172.92209.48222.53230.87221.45
Income Taxes32.8812.44-2.3439.6646.7657.8548.2755.71
Consolidated Net Income95.5745.9224.09133.53163.44164.70183.24166.24
Net Income From Continuing Operations96.7846.8424.04135.79164.63165.66184.00166.24
Net Income96.7846.8424.04135.79164.63165.66184.00166.24
EPS (Recurring)0.120.060.030.170.200.200.230.20
EPS (Basic, Before Extraordinaries)0.120.060.030.160.200.200.220.20
EPS (Diluted)0.120.060.030.160.200.200.220.20
EBITDA180.4488.7667.14213.48235.43252.46236.71-
Non-Operating Income (Expense)18.2939.6629.9631.6249.8735.4463.1824.61
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.620.720.720.16-0.92--
Price To Earnings Ratio40.7724.6717.7717.1817.4818.7517.1420.56
Price To Sales Ratio2.953.303.032.952.933.192.863.52
Gross Margin48.8242.7040.4350.2754.6753.6255.5657.68
Operating Margin13.813.760.7615.8217.6119.7118.7520.86
Net Margin10.675.502.9313.8616.3216.5918.7416.79
Shares Outstanding833.07832.98832.69832.57834.58834.58834.46834.42
Market Capitalization12,362.8012,065.3011,528.7811,686.6211,636.4512,506.1610,988.7613,153.59

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments925.83677.50976.83751.95585.48472.87340.25357.37323.07
Short Term Receivables1,298.611,149.751,031.241,045.111,059.32843.66816.30658.71839.71
Inventories806.87831.67761.99592.22671.51621.11463.52484.72446.00
Other Current Assets152.43267.30204.06128.7783.6390.01103.24152.0572.34
Total Current Assets3,183.752,926.232,974.122,518.052,399.952,027.651,723.301,652.851,681.11
Net Property, Plant & Equipment1,222.261,143.77921.87808.71820.44781.13691.75780.77887.27
Total Investments and Advances172.57177.8663.0165.25105.39113.9740.8648.2471.34
Long-Term Note Receivable---0.000.711.6122.961.632.59
Intangible Assets1,243.581,270.74494.04427.03417.87550.05418.41696.77745.30
Deferred Tax Assets236.55216.54129.1887.56108.27145.39161.4560.1755.63
Other Assets49.3932.6864.159.7311.8011.4111.1613.6615.79
Total Assets6,108.105,767.814,646.363,916.333,864.433,631.203,069.893,254.093,459.03
Short Term Debt Incl. Current Port. of LT Debt686.76455.14168.22148.38370.82328.38274.92236.46392.89
Accounts Payable235.76234.61258.35217.28210.77173.65142.03148.63245.90
Income Tax Payable45.4435.4328.0826.0921.3119.007.572.6123.46
Other Current Liabilities798.70800.36696.86652.82637.81619.54537.97474.08406.29
Total Current Liabilities1,766.671,525.541,151.511,044.571,240.711,140.57962.50861.781,068.54
Long Term Debt128.6692.0171.8215.5575.8386.1517.24317.57384.67
Provision for Risks Charges1.151.830.730.720.750.790.710.750.81
Deferred Tax Liabilities164.14165.0610.9010.140.794.623.648.8111.19
Other Liabilities36.3038.6447.5934.6531.9632.0537.0941.4054.89
Total Liabilities2,096.911,823.081,282.551,105.621,350.051,264.181,021.171,230.311,520.11
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity3,975.413,900.533,363.812,810.712,514.382,367.022,048.722,023.771,938.93
Total Shareholders Equity3,975.413,900.533,363.812,810.712,514.382,367.022,048.722,023.771,938.93
Accumulated Minority Interest35.7844.200.000.000.000.000.000.000.00
Total Equity4,011.203,944.733,363.812,810.712,514.382,367.022,048.722,023.771,938.93
Total Liabilities & Stockholders Equity6,108.105,767.814,646.363,916.333,864.433,631.203,069.893,254.093,459.03
Book Value Per Share4.774.674.033.383.032.862.472.442.34
Tangible Book Value Per Share3.283.153.442.862.532.191.971.601.44
Full-Time Employees27,52727,81127,04825,86324,79522,73921,65021,96623,524
Price to Book Ratio3.072.973.793.373.684.303.263.462.80
Return on Assets8.1712.8415.7114.428.446.938.708.014.44
Return on Equity12.3118.4121.7921.0712.9610.5213.5013.577.90
Return on Invested Capital11.8216.7519.5819.8512.219.4613.3111.486.55
Quick Ratio1.351.371.921.841.391.231.311.361.16
Current Ratio1.801.922.582.411.931.781.791.921.57

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income294.88480.61677.08672.64560.90316.33232.19274.98268.79
Depreciation232.10233.20201.76179.27157.27158.70172.36175.89174.33
Other Funds (Non Cash)27.6927.1623.69-65.1598.9682.65185.4167.9138.10
Funds from Operations554.67740.97902.53786.77817.12557.69589.96518.79481.22
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-238.14-131.69-354.70-243.79-97.76-186.75-110.41-106.28-82.53
Cash from Operating Activities316.53609.28547.83542.98719.36370.93479.55412.50398.69
Capital Expenditures-285.70-434.88-406.85-331.41-234.80-255.68-169.19-86.24-107.13
Net Assets From Acquisitions-38.21-35.67-628.010.000.00-4.38-208.970.000.00
Sale of Fixed Assets and Businesses12.453.506.0612.851.024.971.141.8518.09
Purchase or Sale of Investments-80.73-307.47293.34-189.84-290.81-150.3455.36-3.02-32.64
Purchase of Investments513.73-529.31-3,013.42-1,757.59-1,694.76-1,194.19-1,015.86-1,578.40-1,123.68
Sale Or Maturity of Investments-594.46221.853,306.761,567.751,403.951,043.851,071.221,575.381,091.05
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources36.4315.868.660.250.0039.540.003.650.00
Cash from Investing Activities-355.75-758.66-726.81-508.14-524.59-365.89-321.66-83.76-121.67
Cash Dividends Paid-68.27-75.36-78.80-80.31-61.97-55.65-55.86-55.23-57.23
Change in Capital Stock4.494.4985.749.724.584.48-12.45-6.63-7.65
Repurchase of Common Pref Stock0.000.000.000.000.000.00-16.07-6.68-7.65
Sale of Common Pref Stock4.494.4985.749.724.584.483.620.060.00
Proceedsfrom Stock Options4.494.4985.749.724.584.483.620.060.00
Issuance or Reduction of Debt, Net148.68229.25289.6666.35-241.2247.2592.24-263.49-217.12
Change in Long Term Debt-39.91-0.01-0.000.000.000.77-323.22-0.80
Issuance of Long Term Debt-0.00-45.900.000.0051.190.000.00
Reduction of Long Term Debt-39.91-0.01--45.900.000.00-50.42-323.22-0.80
Net Financing Active Other Cash Flow0.000.00-16.430.000.000.000.000.000.00
Other Financing Activities Uses0.000.00-16.430.000.000.000.000.000.00
Cash from Financing Activities69.56144.08264.87-18.08-311.24-14.4613.78-332.14-282.00
Exchange Rate Effect10.2014.072.65-0.713.569.841.52-0.350.50
Net Change in Cash40.548.7788.5416.04-112.920.43173.19-3.75-4.49
Free Cash Flow130.43345.29222.52344.84578.43174.16348.34344.16299.22
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow169.1942.7676.5646.2218.3478.2234.9123.1827.81
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments795.62860.22925.83918.89786.27777.61
Short Term Receivables1,127.091,314.371,298.611,382.621,100.791,208.50
Inventories847.17850.14806.87879.06853.95881.53
Other Current Assets335.45137.48152.43129.97407.10279.49
Total Current Assets3,105.323,162.213,183.753,310.543,148.113,147.13
Net Property, Plant & Equipment1,201.091,220.691,222.261,285.541,261.211,198.51
Total Investments and Advances170.05167.75172.57110.70109.98133.15
Intangible Assets1,222.461,230.351,243.581,276.451,275.391,254.34
Deferred Tax Assets241.63244.73236.55236.39255.85282.15
Other Assets54.4151.9449.3943.1953.8942.76
Total Assets5,994.956,077.676,108.106,262.836,104.436,058.03
Short Term Debt Incl. Current Port. of LT Debt632.32634.57686.76624.44528.24507.79
Accounts Payable376.53396.13352.26453.90453.30436.77
Income Tax Payable29.2745.0045.4462.2585.91122.68
Other Current Liabilities574.05586.49682.21620.78632.39595.44
Total Current Liabilities1,612.181,662.191,766.671,761.361,699.841,662.67
Long Term Debt122.02125.55128.66129.15131.0659.42
Provision for Risks Charges1.241.291.151.171.951.96
Deferred Tax Liabilities168.92171.22164.14164.39166.99168.49
Other Liabilities27.3531.8636.3026.0926.5740.54
Total Liabilities1,931.711,992.102,096.912,082.162,026.421,933.09
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity4,029.944,050.633,975.414,142.954,037.554,081.84
Total Shareholders Equity4,029.944,050.633,975.414,142.954,037.554,081.84
Accumulated Minority Interest33.3034.9435.7837.7240.4743.10
Total Equity4,063.244,085.574,011.204,180.674,078.024,124.94
Total Liabilities & Stockholders Equity5,994.956,077.676,108.106,262.836,104.436,058.03
Book Value Per Share4.844.864.774.984.844.89
Tangible Book Value Per Share3.373.393.283.443.313.39
Full-Time Employees--27,527---
Price to Book Ratio3.072.912.792.902.863.22
Return on Assets5.026.128.25-11.6712.06
Return on Equity7.529.1312.45-17.7217.48
Return on Invested Capital2.331.120.593.183.954.00
Quick Ratio1.401.391.351.381.351.36
Current Ratio1.931.901.801.881.851.89

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income95.6845.9222.44130.84165.65164.70
Depreciation55.0356.7362.5057.8358.6555.68
Other Funds (Non Cash)2.5512.52-2.5715.19-27.9542.66
Funds from Operations153.26115.1782.38203.87196.35263.04
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-104.09-126.7083.67-91.02-29.46-95.71
Cash from Operating Activities49.16-11.52166.05112.84166.89167.33
Capital Expenditures-45.21-39.10-121.43-79.96-117.66-118.56
Net Assets From Acquisitions0.01-2.32-35.900.000.000.00
Sale of Fixed Assets and Businesses6.773.811.780.091.280.37
Purchase or Sale of Investments75.7341.21-159.61-38.064.09-115.81
Purchase of Investments-26.82-125.061,081.75-416.14-594.74-603.51
Sale Or Maturity of Investments102.55166.27-1,241.36378.09598.83487.69
Other Uses0.000.000.000.000.000.00
Other Sources0.9222.3411.591.582.780.00
Cash from Investing Activities38.2225.94-303.56-116.35-109.51-234.00
Cash Dividends Paid-69.990.000.441.28-77.560.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.702.620.880.291.062.29
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.702.620.880.291.062.29
Proceedsfrom Stock Options0.702.620.880.291.062.29
Issuance or Reduction of Debt, Net7.31-58.1797.28102.2530.340.82
Change in Long Term Debt0.22-40.12-0.010.000.000.00
Issuance of Long Term Debt--0.000.000.000.00
Reduction of Long Term Debt0.22-40.12-0.010.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-66.20-58.8593.99100.63-48.93-0.70
Exchange Rate Effect-0.030.415.794.032.262.07
Net Change in Cash21.15-44.03-37.73101.1410.72-65.30
Free Cash Flow24.16-47.70115.6238.36106.3187.16
Price to Free Cash Flow169.1988.2642.46---

Revenue breakdown

India2024: 660.34M 2025: 730.33M
Others countries2024: 1.12B 2025: 1.34B
Russia2024: 307.02M 2025: 393.65M
United States2024: 1.77B 2025: 1.33B
Global Generics2024: 3.42B 2025: 3.38B
Other segment2024: 25.28M 2025: 24.07M
Pharmaceutical Services and Active Ingredients2024: 400.32M 2025: 393.51M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.04%25.3M833.1M2.92M
2026-10-153.14%26.1M833.0M2.88M
2026-09-303.41%28.4M832.7M2.85M
2026-09-153.48%29.0M832.7M2.89M
2026-08-312.87%23.9M832.7M2.58M
2026-08-142.70%22.5M832.7M2.52M
2026-07-312.51%20.9M832.7M2.70M
2026-07-152.52%21.0M832.7M2.66M
2026-06-302.78%23.2M832.7M2.57M
2026-06-152.74%22.9M832.7M2.38M
2026-05-292.69%22.4M832.7M2.52M
2026-05-152.42%20.2M832.6M2.54M
2026-04-301.89%15.7M832.4M2.31M
2026-04-151.59%13.2M832.4M2.18M
2026-03-311.76%14.6M832.4M2.00M
2026-03-131.65%13.7M832.4M1.75M
2026-02-271.62%13.5M832.4M1.57M
2026-02-131.54%12.8M832.4M1.45M
2026-01-301.51%12.5M832.4M1.26M
2026-01-151.51%12.6M832.4M1.13M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.5010.7013.500.0014.4930.000.000.992-0.0170.001
call5.008.0011.300.009.5100.000.000.938-0.1150.003
call7.505.308.600.006.0270.000.000.900-0.1110.004
call10.002.956.303.484.4791330.000.849-0.1000.005
call12.502.202.602.401.2261,5690.000.762-0.0810.007
call15.000.000.750.350.89432.000.000.541-0.0940.009
call17.500.000.750.001.7740.000.000.323-0.0840.008
call20.000.001.350.002.3790.000.000.267-0.1020.008
call22.500.000.950.002.8560.000.000.237-0.1160.007
put2.500.000.050.005.5840.000.00-0.008-0.0150.001
put5.000.000.750.007.1310.000.00-0.062-0.1140.003
put7.500.000.750.004.8280.000.00-0.100-0.1100.004
put10.000.000.750.003.2480.000.00-0.151-0.0990.005
put12.500.000.750.151.9779.000.00-0.238-0.0790.007
put15.000.002.750.002.9110.000.00-0.459-0.0920.009
put17.501.254.500.003.0130.000.00-0.677-0.0820.008
put20.003.706.700.003.3420.000.00-0.733-0.1000.008
put22.506.209.500.004.2110.000.00-0.762-0.1130.007

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-10SEC
2026-11-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-05SEC
2026-11-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-04SEC
2026-11-02144Filing for proposed sale of securities under Rule 144.SEC
2026-10-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-29SEC
2026-10-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-28SEC
2026-10-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-24SEC
2026-10-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-24SEC
2026-10-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-23SEC
2026-10-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-23SEC
2026-10-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-23SEC
2026-10-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-23SEC
2026-10-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-21SEC
2026-10-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-14SEC
2026-10-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-08SEC
2026-10-076-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-07SEC
2026-10-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-03SEC
2026-09-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-22SEC
2026-09-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-21SEC
2026-09-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-18SEC
2026-09-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-11SEC
2026-09-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-10SEC
2026-09-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-10SEC
2026-08-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-26SEC
2026-08-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-14SEC
2026-08-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-14SEC
2026-08-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-13SEC
2026-08-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-07SEC
2026-08-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-01SEC
2026-07-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-29SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
MORGAN STANLEY1.31%
BlackRock, Inc.1.27%
ROYAL BANK OF CANADA1.11%
Aikya Investment Management Ltd1.09%
Robeco Institutional Asset Management B.V.1.04%
RENAISSANCE TECHNOLOGIES LLC0.88%
DIMENSIONAL FUND ADVISORS LP0.63%
STATE STREET CORP0.50%
JPMORGAN CHASE & CO0.49%
ALLIANCEBERNSTEIN L.P.0.45%

Funds

Fund% owned
AB Emerging Markets Opportunities ETF0.45%
College Retirement Equities Fund - Total Global Stock Account0.24%
VANGUARD EMERGING MARKETS STOCK INDEX FUND0.23%
Avantis Emerging Markets Equity ETF0.22%
State Street(R) SPDR(R) Portfolio Emerging Markets ETF0.18%
VANGUARD GLOBAL MINIMUM VOLATILITY FUND0.16%
EMERGING MARKETS CORE EQUITY 2 PORTFOLIO0.16%
VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND0.10%
Nuveen Emerging Markets Equity Fund0.09%
THE EMERGING MARKETS SERIES0.06%

OakChart. RDY. Cached 15 minutes.